Enliven Therapeutics (ELVN) Share-based Compensation Growth (3y) (2022 - 2026)
Enliven Therapeutics (ELVN) Share-based Compensation Growth (3y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 244.08% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -50.27% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -0.04% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 38.45% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | 48.43% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.43% |
| Dec 31, 2025 | 63.75% |
| Sep 30, 2025 | 5.69% |
| Jun 30, 2025 | 122.52% |
| Mar 31, 2025 | 118.25% |
| Dec 31, 2024 | 76.08% |
| Sep 30, 2024 | 72.81% |
| Jun 30, 2024 | 77.68% |
| Mar 31, 2024 | 68.31% |
| Dec 31, 2023 | 65.11% |
| Sep 30, 2023 | 74.32% |
| Jun 30, 2023 | 96.84% |
| Mar 31, 2023 | 84.53% |
| Dec 31, 2022 | 111.35% |
| Sep 30, 2022 | 52.57% |
| Jun 30, 2022 | 52.67% |
| Mar 31, 2022 | 90.23% |